Effect of Rozanolixizumab on Ocular Symptoms in Patients with Generalized Myasthenia Gravis: A Post Hoc Item-level Analysis of Myasthenia Gravis-specific Outcomes in MycarinG (P1-11.006)
To investigate the effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis (gMG) in the Phase 3 MycarinG study (NCT03971422).
Authors
- Jos Bloemers (ORCID: https://orcid.org/0000-0001-5637-7606)
- John Vissing (ORCID: https://orcid.org/0000-0001-6144-8544)
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Fiona Grimson
- Robert M. Pascuzzi (ORCID: https://orcid.org/0000-0003-0616-3073)
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Zabeen Mahuwala
- Thaïs Tarancón
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
Institutions
- University of Copenhagen (DK)
- Indiana University Health (US)
- University Health Network (CA)
- University of Kentucky (US)
- University of California, Irvine (US)
- University of South Florida (US)
- Rigshospitalet (DK)
- Indiana University – Purdue University Indianapolis (US)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208795
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00